Summary of Purpose
To assess the efficacy of early thrombolytic therapy with recombinant tissue-type plasminogen activator in the treatment of acute ischemic stroke and to assess the feasibility of conducting a larger, multi-center trial.Read More →
The following dates are available for this trial. Trial information last updated on 10 December 2001.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Randomized, stratified, double-blind, placebo-controlled trial of 27 patients. Stratification was by whether treatment was begun within 90 minutes or 91 to 180 minutes from onset.